Table 1 Characteristics of the study population at baseline presented as proportion, mean (SD) or median (quartiles)
Variable | Cases | Controls | p-value |
|---|---|---|---|
n = 153 | n = 52 | ||
Age, mean (SD) | 65.9 (13.5) | 65.7 (16.5) | 0.565 |
BMI, mean | 26.5 (4.9) | 27.8 (6.1) | 0.370 |
Hemodialysis vintage, mean, months | 10.3 (33.9) | 74.8 (45.1) | < 0.001 |
StKt/V, median | 2.0 (1.4–2.4) | 2.2 (2–2.4) | 0.099 |
Female, n (%) | 60 (39%) | 13 (25%) | 0.064 |
Tobacco: | |||
Yes cigarettes, ever | 48 (46%) | 37 (88%) | < 0.001 |
Never | 57 (54%) | 4 (10%) | < 0.001 |
Yes snuff, ever | 0 (0%) | 1 (2%) | 0.6 |
Missing data | 48 (31%) | 11 (21%) | 0.22 |
Diagnosis: | |||
Glomerulonephritis | 25 (16%) | 12 (28%) | 0.28 |
Diabetes Mellitus | 42 (28%) | 10 (23%) | 0.24 |
TIN/Tubulointerstitial nephritis | 24 (16%) | 3 (7%) | 0.07 |
PCKD/Polycystic kidney disease | 15 (10%) | 3 (7%) | 0.38 |
Nephrosclerosis/Hypertension | 35 (23%) | 11 (26%) | 0.80 |
Other | 11 (7%) | 4 (9%) | 0.90 |
Ongoing medication: | |||
Calcium channel blockers | 61 (48%) | 19 (43%) | 0.608 |
Alfa-1 receptor blockers | 40 (31%) | 6 (14%) | 0.023 |
Furosemides | 79 (62%) | 26 (59%) | 0.758 |
Beta-blockers | 94 (73%) | 31 (70%) | 0.757 |
ACE-inhibitors | 34 (27%) | 11 (25%) | 0.839 |
ARB:s | 56 (44%) | 12 (27%) | 0.054 |
ASA | 69 (54%) | 22 (50%) | 0.654 |
Vitamin-K antagonists | 9 (7%) | 3 (7%) | 0.962 |
Statins | 68 (53%) | 22 (50%) | 0.720 |